Silverback Therapeutics
ARS Pharmaceuticals is dedicated to developing patient-friendly, needle-free treatments for severe allergic reactions, including an investigational intranasal epinephrine spray called ARS-1, which aims to be a reliable, easy-to-use, and portable alternative to auto-injectors. The company focuses on innovative drug delivery technologies and aims to provide safer, more accessible emergency treatment options for allergy sufferers.
Industries
Nr. of Employees
small (1-50)
Silverback Therapeutics
Seattle, Washington, United States, North America
Products
Intranasal epinephrine nasal spray (needle-free)
A low-dose aqueous intranasal epinephrine formulation intended to provide rapid systemic absorption comparable to intramuscular injection for emergency treatment of severe allergic reactions; designed for needle-free, portable administration and developed with a mucosal absorption-enhancing excipient.
Intranasal epinephrine nasal spray (needle-free)
A low-dose aqueous intranasal epinephrine formulation intended to provide rapid systemic absorption comparable to intramuscular injection for emergency treatment of severe allergic reactions; designed for needle-free, portable administration and developed with a mucosal absorption-enhancing excipient.
Services
Patient savings and support programs
Co-pay assistance and patient/caregiver support resources to facilitate access to therapy for qualifying patients.
Patient savings and support programs
Co-pay assistance and patient/caregiver support resources to facilitate access to therapy for qualifying patients.
Expertise Areas
- Clinical trial management (PK/PD and crossover designs)
- Intranasal drug formulation and mucosal delivery
- Pharmacokinetics and pharmacodynamics assessment
- Regulatory strategy and FDA engagement (IND/NDA, expedited pathways)
Key Technologies
- Intranasal drug delivery
- Nasal/mucosal absorption enhancing excipients
- Pharmacokinetic (PK) and pharmacodynamic (PD) analysis
- Bioequivalence testing